# Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

> **NCT05007262** · PHASE2 · UNKNOWN · sponsor: **Guizhou Bailing Group Pharmaceutical Co Ltd** · enrollment: 240 (actual)

## Conditions studied

- Type2 Diabetes
- Diabetic Retinopathy

## Interventions

- **DRUG:** Tangningtongluo tablets
- **DRUG:** Calcium dobesilate capsules

## Key facts

- **NCT ID:** NCT05007262
- **Lead sponsor:** Guizhou Bailing Group Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-31
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007262, "Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05007262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*